SCINOPHARMA TAIWAN LIMITED

Business Nature: Manufacturer (API and Injectable Drug Developer)

Company Profile:

Scinopharm Taiwan Limited is a leading international manufacturer specializing in the development and production of Active Pharmaceutical Ingredients (APIs) and injectable drug products. Founded in 1997, the company operates state-of-the-art manufacturing facilities that comply with international regulatory standards, including US FDA, EU EMA, and Japan PMDA approvals. Scinopharm focuses on high-barrier, complex synthetic processes and provides comprehensive contract development and manufacturing organization (CDMO) services to global pharmaceutical companies. Their expertise spans from early-stage process development to large-scale commercial production of high-quality oncology and specialty pharmaceutical ingredients.

SCINOPHARMA TAIWAN LIMITED manufactures and sells the following products:

Active Pharmaceutical Ingredients (APIs) for a wide range of therapeutic areas, including:

Oncology products, such as Gemcitabine HCl, Pemetrexed Disodium, Irinotecan HCl, Docetaxel, Paclitaxel, and Capecitabine.

Immunosuppressants, such as Azathioprine, Mycophenolate Mofetil, Tacrolimus, Sirolimus, and Everolimus.

Anti-infectives, including Voriconazole.

Cardiovascular medications.

Central Nervous System (CNS) medications.

Additionally, they develop and manufacture certain finished dosage forms derived from these APIs.